Our Team

  • Finnegan-square-v2

  • Paul Finnegan, M.D., M.B.A.

    Chief Executive Officer

    Dr. Finnegan is Chief Executive Officer of Angiocrine Bioscience. He has more than 20 years of life science management experience in the biotechnology, pharmaceutical, and healthcare industries – including extensive operational and strategic leadership roles in venture-backed start-ups and multi-billion dollar publically listed global companies, complemented by service on boards of both private and public biotechnology companies. Most recently, Dr. Finnegan has been advising boards and senior management of emerging biotechnology and pharmaceutical companies on strategic, commercial, business development, clinical, and regulatory matters, including companies focused on cellular immunotherapy (for cancer) and cellular regenerative therapies. From 2012-2014, Dr. Finnegan served as Vice President and General Manager, Asia-Pacific for ViroPharma, Inc., which was acquired by Shire PLC for $4.2 billion. In this role, he initiated ViroPharma’s business in the Asia-Pacific region, and launched and developed Cinryze® and commercialized Plenadren®. Dr. Finnegan concurrently served as Director (Board) of Imprimis Pharmaceuticals (2012-2013) and on the Audit, Compensation, and Nomination & Governance Committees. From 2008-2011, Dr. Finnegan was retained exclusively to manage start-ups wholly funded by Avalon Ventures, where he was CEO of Avelas BioSciences and InCode Biotherapeutics, participated as board observer for various Avalon portfolio companies, and provided commercial, clinical and regulatory due diligence for new Avalon Fund investments. From 2007-2008, Dr. Finnegan served as founding CEO of Cecoura Therapeutics, a start-up wholly owned by Paramount BioSciences. From 2001-2007, Dr. Finnegan served as Vice President of Commercial Operations and Development, and then later as Vice President of Global Strategic Marketing for Alexion Pharmaceuticals, Inc. While at Alexion, Dr. Finnegan co-founded the paroxysmal nocturnal hemoglobinuria clinical program for eculizumab, built the first commercial organization, and initiated and led the global commercialization of Soliris® – the most successful ultra-orphan product launch in 2007. From 1998-2000, Dr. Finnegan was Senior Director, Global Medical Marketing, APLAC Region for Searle, a division of Monsanto and then of Pharmacia Corp in 2000. While at Searle, Dr. Finnegan played key roles in his market region for the launch of Celebrex® – the most successful pharmaceutical product launch in 1999. Prior to Searle, Dr. Finnegan was a fellowship-trained interventional radiologist and an entrepreneur in the healthcare provider segment. Dr. Finnegan earned his M.D., C.M. from McGill University, Montreal, Canada, and his M.B.A. in Finance and Strategy from the University of Chicago, Booth Graduate School of Business and is a Fellow of the Royal College of Physicians, Canada (FRCPC) and a Member of the American Society of Hematology (ASH).

  • Davis-square-v2

  • C. Geoffrey Davis, Ph.D.

    President, CSO & Co-Founder

    Dr. Davis is President and Chief Scientific Officer of Angiocrine Bioscience. Formerly, he served as Chief Scientific Officer of Abgenix, Inc. in Fremont, California. He led the development of the XenoMouse technology, which provided the basis for Abgenix to grow from a Cell Genesys spinout and be acquired by Amgen. During this time, he advanced three antibody product candidates into clinical trials and was instrumental in identifying, structuring, and managing over 30 corporate partnerships. To date, these partnerships have resulted in 11 antibody product candidates derived from XenoMouse technology entering clinical trials and two being approved for the market. Dr. Davis received his Ph.D. from the University of California, San Francisco and completed his postdoctoral work in the laboratory of Nobel Laureates Joseph L. Goldstein and Michael S. Brown at The University of Texas, Southwestern. Prior to founding Abgenix, Dr. Davis was a faculty member at UCSF, an investigator with the Howard Hughes Medical Institute, and Director of Immunology at both Repligen Corporation and Cell Genesys, Inc. He also consults for several biotechnology/pharmaceutical companies and serves on the Board of Directors for four companies.

  • Jaskowiak-square-v2

  • John R. Jaskowiak

    Vice President, Corporate Development

    Mr. Jaskowiak is Vice President, Corporate Development at Angiocrine Bioscience responsible for leading the commercialization of the E-CEL™ platform. John comes to Angiocrine Bioscience with over 25 years of commercial experience within the Life Sciences and Diagnostics industries. Most recently he was Vice President of Marketing and Sales at SDIX, where he led the transformation of the commercial team into a focused life science organization, developing Go-To-Market strategies and supporting business plans for its core business and new business growth initiatives for its two complementary technologies for the generation and isolation of novel monoclonal antibodies. He has also held various management roles at Hewlett-Packard, Agilent Technologies, Affymetrix, ExonHit Therapeutics, and Meso Scale Diagnostics. John has a degree in Biology from Temple University, Philadelphia, PA.

  • Nolan-square-v2


  • Daniel J. Nolan, Ph.D.

    Director of Research

    Dr. Nolan is Director of Research at Angiocrine Bioscience. An alumni of Stony Brook University, Daniel remained there for his graduate studies ultimately performing his research in the laboratory of Dr. Vivek Mittal. Dr. Mittal fostered Daniel’s interest in vascular biology with work centered on the temporal contribution of endothelial progenitor cells to tumor vasculature. His exposure to a wide range of technology led to his recruitment by Dr. Shahin Rafii at Weill Cornell Medical College. This became fertile grounds for advances as Dr. Rafii’s team was rapidly accelerating their understanding of the capacities of the E-CEL™ platform and Daniel was transforming the technological landscape of protocols within the laboratory to achieve these advances. His own work focused on the distinctions between the endothelial cells of the various tissues. The protocols he developed were the foundations to establish a series of tissue specific microvascular endothelial cells. An accomplished flow cytometrist and microscopist, Daniel continues his characterizations of distinct populations of endothelial cells at Angiocrine Bioscience.

  • Breneman-square-v2

  • Margie Breneman, PMP

    Senior Director, Project Management

    Ms. Breneman is Senior Director, Project Management at Angiocrine Bioscience. Margie has over 20 years of experience leading teams in medical device, pharmaceutical and biotech companies. As QA Associate Director of Strategic Initiatives at Illumina, Margie led the Quality Systems Improvement Program to ensure compliance to ISO and FDA requirements for DNA sequencing products, including the MiSeqDx System, the first FDA approved device for in vitro diagnostic (IVD) testing. Margie also headed teams at Guidant and Abbott in areas of process improvement (Lean, Kaizen, 5S), facility design, cost reduction, software development, and technology transfer. In 2007, she received the Abbott Vascular President’s Award for the implementation of the CAMSTAR MES system to capture cGMP data for XIENCE, the market-leading drug eluting stent. Margie has a degree in Industrial Engineering from California Polytechnic State University, San Luis Obispo, a professional certificate in Regulatory Affairs from San Diego State University, and is a certified Project Management Professional (PMP).